Native human antibodies are defined as those that arise naturally as the result of the functioning of an intact human immune system. The utility of native antibodies for the treatment of human viral diseases has been established through experience with hyperimmune human globulins. Native antibodies, as a class, differ in some respects from those obtained by recombinant library methods (phage or transgenic mouse) and possess distinct properties that may make them ideal therapeutics for human viral diseases. Methods for cloning native human antibodies have been beset by technical problems, yet many antibodies specific for viral antigens have been cloned. In the present review, we discuss native human antibodies and ongoing improvements in cloning methods that should facilitate the creation of novel, potent antiviral therapeutics obtained from the native human antibody repertoire.
Chapter PDF
Similar content being viewed by others
Keywords
- Respiratory Syncytial Virus
- West Nile Virus
- Severe Acute Respiratory Syndrome
- Rabies Virus
- Human Monoclonal Antibody
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
References
Amersdorfer P, Wong C, Smith T, Chen S, Deshpande S, Sheridan R, Marks JD (2002) Genetic and immunological comparison of anti-botulinum type A antibodies from immune and non-immune human phage libraries. Vaccine 20:1640–1648
Ames RS, Tornetta MA, McMillan LJ, Kaiser KF, Holmes SD, Appelbaum E, Cusimano DM, Theisen TW, Gross MS, Jones CS, et al (1995) Neutralizing murine monoclonal antibodies to human IL-5 isolated from hybridomas and a filamentous phage Fab display library. J Immunol 154:6355–6364
Andris JS, Ehrlich PH, Ostberg L, Capra JD (1992) Probing the human antibody repertoire to exogenous antigens. Characterization of the H and L chain V region gene segments from anti-hepatitis B virus antibodies. J Immunol 149:4053–4059
Arakelov S, Gorny MK, Williams C, Riggin CH, Brady F, Collett MS, Zolla-Pazner S (1993) Generation of neutralizing anti-B19 parvovirus human monoclonal antibodies from patients infected with human immunodeficiency virus. J Infect Dis 168:580–585
Arinbjarnarson S, Valdimarsson H (2002) Generation of heterohybridomas secreting human immunoglobulins; pokeweed mitogen prestimulation is highly effective but phytohemagglutinin drives most B cells into apoptosis. J Immunol Methods 259:139–148
Aujard Y, Fauroux B (2002) Risk factors for severe respiratory syncytial virus infection in infants. Respir Med 96 [Suppl B]:S9–S14
Babcook JS, Leslie KB, Olsen OA, Salmon RA, Schrader JW (1996) A novel strategy for generating monoclonal antibodies from single, isolated lymphocytes producing antibodies of defined specificities. Proc Natl Acad Sci U S A 93:7843–7848
Bailey SM, Murnane JP (2006) Telomeres, chromosome instability and cancer. Nucleic Acids Res 34:2408–2417
Bakker AB, Marissen WE, Kramer RA, Rice AB, Weldon WC, Niezgoda M, Hanlon CA, Thijsse S, Backus HH, de Kruif J, Dietzschold B, Rupprecht CE, Goudsmit J (2005) Novel human monoclonal antibody combination effectively neutralizing natural rabies virus variants and individual in vitro escape mutants. J Virol 79:9062–9068
Banchereau J, Rousset F (1991) Growing human B lymphocytes in the CD40 system. Nature 353:678–679
Barbas CF 3rd (1993) Recent advances in phage display. Curr Opin Biotechnol 4:526–530
Bazin R, Lemieux R (1989) Increased proportion of B cell hybridomas secreting monoclonal antibodies of desired specificity in cultures containing macrophage-derived hybridoma growth factor (IL-6). J Immunol Methods 116:245–249
Biron KK (2006) Antiviral drugs for cytomegalovirus diseases. Antiviral Res 71:154–163
Boder ET, Wittrup KD (1997) Yeast surface display for screening combinatorial polypeptide libraries. Nat Biotechnol 15:553–557
Boeckh M, Bowden RA, Storer B, Chao NJ, Spielberger R, Tierney DK, Gallez-Hawkins G, Cunningham T, Blume KG, Levitt D, Zaia JA (2001) Randomized, placebo-controlled, double-blind study of a cytomegalovirus-specific monoclonal antibody (MSL-109) for prevention of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 7:343–351
Boeckh M, Leisenring W, Riddell SR, Bowden RA, Huang ML, Myerson D, Stevens-Ayers T, Flowers ME, Cunningham T, Corey L (2003) Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood 101:407–414
Borrebaeck CA, Danielsson L, Moller SA (1987) Human monoclonal antibodies produced from L-leucine methyl ester-treated and in vitro immunized peripheral blood lymphocytes. Biochem Biophys Res Commun 148:941–946
Borrebaeck CA, Danielsson L, Moller SA (1988) Human monoclonal antibodies produced by primary in vitro immunization of peripheral blood lymphocytes. Proc Natl Acad Sci USA 85:3995–3999
Borucki MJ, Spritzler J, Asmuth DM, Gnann J, Hirsch MS, Nokta M, Aweeka F, Nadler PI, Sattler F, Alston B, Nevin TT, Owens S, Waterman K, Hubbard L, Caliendo A, Pollard RB (2004) A phase II, double-masked, randomized, placebo-controlled evaluation of a human monoclonal anti-Cytomegalovirus antibody (MSL-109) in combination with standard therapy versus standard therapy alone in the treatment of AIDS patients with cytomegalovirus retinitis. Antiviral Res 64:103–111
Bradbury AR, Marks JD (2004) Antibodies from phage antibody libraries. J Immunol Methods 290:29–49
Brezinschek HP, Brezinschek RI, Lipsky PE (1995) Analysis of the heavy chain repertoire of human peripheral B cells using single-cell polymerase chain reaction. J Immunol 155:190–202
Broliden K, Tolfvenstam T, Norbeck O (2006) Clinical aspects of parvovirus B19 infection. J Intern Med 260:285–304
Bron D, Delforge A, Lagneaux L, De Martynoff G, Bosmans E, Van der Auwera P, Snoeck R, Burny A, Stryckmans P (1990) Production of human monoclonal IgG antibodies reacting with cytomegalovirus (CMV). J Immunol Methods 130:209–216
Brown NA, Miller G (1982) Immunoglobulin expression by human B lymphocytes clonally transformed by Epstein Barr virus. J Immunol 128:24–29
Butler JL, Lane HC, Fauci AS (1983) Delineation of optimal conditions for producing mouse-human heterohybridomas from human peripheral blood B cells of immunized subjects. J Immunol 130:165–168
Carman WF, Trautwein C, van Deursen FJ, Colman K, Dornan E, McIntyre G, Waters J, Kliem V, Muller R, Thomas HC, Manns MP (1996) Hepatitis B virus envelope variation after transplantation with and without hepatitis B immune globulin prophylaxis. Hepatology 24:489–493
Carroll WL, Thielemans K, Dilley J, Levy R (1986) Mouse x human heterohybridomas as fusion partners with human B cell tumors. J Immunol Methods 89:61–72
Casadevall A, Pirofski LA (2005) The potential of antibody-mediated immunity in the defence against biological weapons. Expert Opin Biol Ther 5:1359–1372
Casadevall A, Dadachova E, Pirofski LA (2004) Passive antibody therapy for infectious diseases. Nat Rev Microbiol 2:695–703
Casali P, Inghirami G, Nakamura M, Davies TF, Notkins AL (1986) Human monoclonals from antigen-specific selection of B lymphocytes and transformation by EBV. Science 234:476–479
CDC (1984) Postexposure prophylaxis of hepatitis B. Morb Mortal Wkly Rep 33:285–290
CDC (1985) Recommendations for protection against viral hepatitis. Morb Mortal Wkly Rep 34:313–324, 329–335
CDC (1996) Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). Centers for Disease Control and Prevention. MMWR Recomm Rep 45:1–36
CDC (1997a) MSL-109 adjuvant therapy for cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome: the Monoclonal Antibody Cytomegalovirus Retinitis Trial. The Studies of Ocular Complications of AIDS Research Group. AIDS Clinical Trials Group. Arch Ophthalmol 115:1528–1536
CDC (1997b) Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. The PREVENT Study Group. Pediatrics 99:93–99
CDC (1998) Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics 102:531–537
CDC (2006) A new product (VariZIG) for postexposure prophylaxis of varicella available under an investigational new drug application expanded access protocol. MMWR Morb Mortal Wkly Rep 55:209–210
Cerino A, Boender P, La Monica N, Rosa C, Habets W, Mondelli MU (1993) A human monoclonal antibody specific for the N terminus of the hepatitis C virus nucleocapsid protein. J Immunol 151:7005–7015
Champion JM, Kean RB, Rupprecht CE, Notkins AL, Koprowski H, Dietzschold B, Hooper DC (2000) The development of monoclonal human rabies virus-neutralizing antibodies as a substitute for pooled human immune globulin in the prophylactic treatment of rabies virus exposure. J Immunol Methods 235:81–90
Chiorazzi N, Wasserman RL, Kunkel HG (1982) Use of Epstein-Barr virus-transformed B cell lines for the generation of immunoglobulin-producing human B cell hybridomas. J Exp Med 156:930–935
Cieplinski W, Reardon P, Testa MA (1983) Non-random human chromosome distribution in human-mouse myeloma somatic cell hybrids. Cytogenet Cell Genet 35:93–99
Cole SP, Campling BG, Louwman IH, Kozbor D, Roder JC (1984) A strategy for the production of human monoclonal antibodies reactive with lung tumor cell lines. Cancer Res 44:2750–2753
Colucci G, Kohtz DS, Waksal SD (1986) Preparation and characterization of human monoclonal antibodies directed against the hepatitis B virus surface antigen. Liver 6:145–152
Cote RJ, Morrissey DM, Houghton AN, Beattie EJ Jr, Oettgen HF, Old LJ (1983) Generation of human monoclonal antibodies reactive with cellular antigens. Proc Natl Acad Sci USA 80:2026–2030
Counter CM, Avilion AA, LeFeuvre CE, Stewart NG, Greider CW, Harley CB, Bacchetti S (1992) Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity. EMBO J 11:1921–1929
Croce CM, Linnenbach A, Hall W, Steplewski Z, Koprowski H (1980) Production of human hybridomas secreting antibodies to measles virus. Nature 288:488–489
Darveau A, Chevrier MC, Neron S, Delage R, Lemieux R (1993) Efficient preparation of human monoclonal antibody-secreting heterohybridomas using peripheral B lymphocytes cultured in the CD40 system. J Immunol Methods 159:139–143
Daugherty PS, Olsen MJ, Iverson BL, Georgiou G (1999) Development of an optimized expression system for the screening of antibody libraries displayed on the Escherichia coli surface. Protein Eng 12:613–621
de Kruif J, Bakker AB, Marissen WE, Kramer RA, Throsby M, Rupprecht CE, Goudsmit J (2006) A human monoclonal antibody cocktail as a novel component of rabies postexposure prophylaxis. Annu Rev Med 58:359–368
Desgranges C, Paire J, Pichoud C, Souche S, Frommel D, Trepo C (1987) High affinity human monoclonal antibodies directed against hepatitis B surface antigen. J Virol Methods 16:281–292
Dessain SK, Adekar SP, Stevens JB, Carpenter KA, Skorski ML, Barnoski BL, Goldsby RA, Weinberg RA (2004) High efficiency creation of human monoclonal antibody-producing hybridomas. J Immunol Methods 291:109–122
DeVincenzo JP, Hirsch RL, Fuentes RJ, Top FH Jr (2000) Respiratory syncytial virus immune globulin treatment of lower respiratory tract infection in pediatric patients undergoing bone marrow transplantation—a compassionate use experience. Bone Marrow Transplant 25:161–165
Di Paolo D, Tisone G, Piccolo P, Lenci I, Zazza S, Angelico M (2004) Low-dose hepatitis B immunoglobulin given “on demand” in combination with lamivudine: a highly cost-effective approach to prevent recurrent hepatitis B virus infection in the long-term follow-up after liver transplantation. Transplantation 77:1203–1208
Dietzschold B, Gore M, Casali P, Ueki Y, Rupprecht CE, Notkins AL, Koprowski H (1990) Biological characterization of human monoclonal antibodies to rabies virus. J Virol 64:3087–3090
Dorfman N, Dietzschold B, Kajiyama W, Fu ZF, Koprowski H, Notkins AL (1994) Development of human monoclonal antibodies to rabies. Hybridoma 13:397–402
Drobyski WR, Gottlieb M, Carrigan D, Ostberg L, Grebenau M, Schran H, Magid P, Ehrlich P, Nadler PI, Ash RC (1991) Phase I study of safety and pharmacokinetics of a human anticytomegalovirus monoclonal antibody in allogeneic bone marrow transplant recipients. Transplantation 51:1190–1196
Ebeling SB, Bos HM, Slater R, Overkamp WJ, Cuthbert AP, Newbold RF, Zdzienicka MZ, Aarden LA (1998) Human chromosome 21 determines growth factor dependence in human/mouse B-cell hybridomas. Cancer Res 58:2863–2868
Ehrlich PH, Moustafa ZA, Justice JC, Harfeldt KE, Kelley RL, Ostberg L (1992) Characterization of human monoclonal antibodies directed against hepatitis B surface antigen. Hum Antibodies Hybridomas 3:2–7
Eid AJ, Brown RA, Patel R, Razonable RR (2006) Parvovirus B19 infection after transplantation: a review of 98 cases. Clin Infect Dis 43:40–48
Emanuel D, Gold J, Colacino J, Lopez C, Hammerling U (1984) A human monoclonal antibody to cytomegalovirus (CMV). J Immunol 133:2202–2205
Enssle K, Kurrle R, Kohler R, Muller H, Kanzy EJ, Hilfenhaus J, Seiler FR (1991) A rabies-specific human monoclonal antibody that protects mice against lethal rabies. Hybridoma 10:547–556
Ephrussi B, Weiss MC (1969) Hybrid somatic cells. Sci Am 220:26–35
Ergaz Z, Ornoy A (2006) Parvovirus B19 in pregnancy. Reprod Toxicol 21:421–435
Faller G, Vollmers HP, Weiglein I, Marx A, Zink C, Pfaff M, Muller-Hermelink HK (1990) HAB-1, a new heteromyeloma for continuous production of human monoclonal antibodies. Br J Cancer 62:595–598
Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE (2005) Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med 352:1749–1759
Ferretti G, Merli M, Ginanni Corradini S, Callejon V, Tanzilli P, Masini A, Ferretti S, Iappelli M, Rossi M, Rivanera D, Lilli D, Mancini C, Attili A, Berloco P (2004) Low-dose intramuscular hepatitis B immune globulin and lamivudine for long-term prophylaxis of hepatitis B recurrence after liver transplantation. Transplant Proc 36:535–538
Fiore AE, Wasley A, Bell BP (2006) Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 55:1–23
Foung S, Perkins S, Kafadar K, Gessner P, Zimmermann U (1990) Development of microfusion techniques to generate human hybridomas. J Immunol Methods 134:35–42
Foung SK, Perkins S, Raubitschek A, Larrick J, Lizak G, Fishwild D, Engleman EG, Grumet FC (1984) Rescue of human monoclonal antibody production from an EBV-transformed B cell line by fusion to a human-mouse hybridoma. J Immunol Methods 70:83–90
Foung SK, Perkins S, Koropchak C, Fishwild DM, Wittek AE, Engleman EG, Grumet FC, Arvin AM (1985) Human monoclonal antibodies neutralizing varicella-zoster virus. J Infect Dis 152:280–285
Foung SK, Perkins S, Bradshaw P, Rowe J, Rabin LB, Reyes GR, Lennette ET (1989) Human monoclonal antibodies to human cytomegalovirus. J Infect Dis 159:436–443
Fowler KB, Stagno S, Pass RF, Britt WJ, Boll TJ, Alford CA (1992) The outcome of congenital cytomegalovirus infection in relation to maternal antibody status. N Engl J Med 326:663–667
Gandhi MK, Khanna R (2004) Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments. Lancet Infect Dis 4:725–738
Gebauer W, Lindl T (1990) Construction of human monoclonal antibodies against rabies NS-protein antigen by Epstein-Barr virus transformation. Arzneimittelforschung 40:718–722
Geetha D, Zachary JB, Baldado HM, Kronz JD, Kraus ES (2000) Pure red cell aplasia caused by Parvovirus B19 infection in solid organ transplant recipients: a case report and review of literature. Clin Transplant 14:586–591
Ghany MG, Ayola B, Villamil FG, Gish RG, Rojter S, Vierling JM, Lok AS (1998) Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis. Hepatology 27:213–222
Ghosh S, Champlin RE, Englund J, Giralt SA, Rolston K, Raad I, Jacobson K, Neumann J, Ippoliti C, Mallik S, Whimbey E (2000) Respiratory syncytial virus upper respiratory tract illnesses in adult blood and marrow transplant recipients: combination therapy with aerosolized ribavirin and intravenous immunoglobulin. Bone Marrow Transplant 25:751–755
Gigler A, Dorsch S, Hemauer A, Williams C, Kim S, Young NS, Zolla-Pazner S, Wolf H, Gorny MK, Modrow S (1999) Generation of neutralizing human monoclonal antibodies against parvovirus B19 proteins. J Virol 73:1974–1979
Gish RG, McCashland T (2006) Hepatitis B in liver transplant recipients. Liver Transpl 12:S54–S64
Goldsmith JC, Eller N, Mikolajczyk M, Manischewitz J, Golding H, Scott DE (2004) Intravenous immunoglobulin products contain neutralizing antibodies to vaccinia. Vox Sang 86:125–129
Gray F, Kenney JS, Dunne JF (1995) Secretion capture and report web: use of affinity derivatized agarose microdroplets for the selection of hybridoma cells. J Immunol Methods 182:155–163
Griffiths AD, Williams SC, Hartley O, Tomlinson IM, Waterhouse P, Crosby WL, Kontermann RE, Jones PT, Low NM, Allison TJ, et al (1994) Isolation of high affinity human antibodies directly from large synthetic repertoires. EMBO J 13:3245–3260
Grunow R, Jahn S, Porstmann T, Kiessig SS, Steinkellner H, Steindl F, Mattanovich D, Gurtler L, Deinhardt F, Katinger H, et al (1988) The high efficiency, human B cell immortalizing heteromyeloma CB-F7. Production of human monoclonal antibodies to human immunodeficiency virus. J Immunol Methods 106:257–265
Gustafsson B, Jondal M, Sundqvist VA (1991) SPAM-8, a mouse-human heteromyeloma fusion partner in the production of human monoclonal antibodies. Establishment of a human monoclonal antibody against cytomegalovirus. Hum Antibodies Hybridomas 2:26–32
Hadlock KG, Rowe J, Perkins S, Bradshaw P, Song GY, Cheng C, Yang J, Gascon R, Halmos J, Rehman SM, McGrath MS, Foung SK (1997) Neutralizing human monoclonal antibodies to conformational epitopes of human T-cell lymphotropic virus type 1 and 2 gp46. J Virol 71:5828–5840
Hadlock KG, Lanford RE, Perkins S, Rowe J, Yang Q, Levy S, Pileri P, Abrignani S, Foung SK (2000) Human monoclonal antibodies that inhibit binding of hepatitis C virus E2 protein to CD81 and recognize conserved conformational epitopes. J Virol 74:10407–10416
Hangartner L, Zinkernagel RM, Hengartner H (2006) Antiviral antibody responses: the two extremes of a wide spectrum. Nat Rev Immunol 6:231–243
Harris JF, Koropatnick J, Pearson J (1990) Spontaneous and radiation-induced genetic instability of heteromyeloma hybridoma cells. Mol Biol Med 7:485–493
Harris JF, Hawley RG, Hawley TS, Crawford-Sharpe GC (1992) Increased frequency of both total and specific monoclonal antibody producing hybridomas using a fusion partner that constitutively expresses recombinant IL-6. J Immunol Methods 148:199–207
Hartmann G, Krieg AM (2000) Mechanism and function of a newly identified CpG DNA motif in human primary B cells. J Immunol 164:944–953
Heijtink R, Paulij W, van Bergen P, van Roosmalen M, Rohm D, Eichentopf B, Muchmore E, de Man R, Osterhaus A (1999) In vivo activity of a mixture of two human monoclonal antibodies (anti-HBs) in a chronic hepatitis B virus carrier chimpanzee. J Gen Virol 80:1529–1535
Heijtink RA, Kruining J, Weber YA, de Man RA, Schalm SW (1995) Anti-hepatitis B virus activity of a mixture of two monoclonal antibodies in an “inhibition in solution” assay. Hepatology 22:1078–1083
Henderson DA, Inglesby TV, Bartlett JG, Ascher MS, Eitzen E, Jahrling PB, Hauer J, Layton M, McDade J, Osterholm MT, O’Toole T, Parker G, Perl T, Russell PK, Tonat K (1999) Smallpox as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA 281:2127–2137
Hirano T (1998) Interleukin 6 and its receptor: ten years later. Int Rev Immunol 16:249–284
Hoffmann P, Jimenez-Diaz M, Weckesser J, Bessler WG (1996) Murine bone marrow-derived macrophages constitute feeder cells for human B cell hybridomas. J Immunol Methods 196:85–91
Hollinger FB, Liang TJ (2001) Hepatitis B virus. In: Knipe DM, Howley PM (eds) Fields virology. Lippincott Williams and Wilkins, Philadelphia, pp 2971–3036
Holt SE, Glinsky VV, Ivanova AB, Glinsky GV (1999) Resistance to apoptosis in human cells conferred by telomerase function and telomere stability. Mol Carcinog 25:241–248
Hooper JW, Custer DM, Thompson E (2003) Four-gene-combination DNA vaccine protects mice against a lethal vaccinia virus challenge and elicits appropriate antibody responses in nonhuman primates. Virology 306:181–195
Ichimori Y, Sasano K, Itoh H, Hitotsumachi S, Kimura Y, Kaneko K, Kida M, Tsukamoto K (1985) Establishment of hybridomas secreting human monoclonal antibodies against tetanus toxin and hepatitis B virus surface antigen. Biochem Biophys Res Commun 129:26–33
Ichimori Y, Harada K, Hitotsumachi S, Tsukamoto K (1987) Establishment of hybridoma secreting human monoclonal antibody against hepatitis B virus surface antigen. Biochem Biophys Res Commun 142:805–812
Ip HM, Lelie PN, Wong VC, Kuhns MC, Reesink HW (1989) Prevention of hepatitis B virus carrier state in infants according to maternal serum levels of HBV DNA. Lancet 1:406–410
Jessup CF, Baxendale H, Goldblatt D, Zola H (2000) Preparation of human-mouse heterohybridomas against an immunising antigen. J Immunol Methods 246:187–202
Kabir A, Alavian SM, Ahanchi N, Malekzadeh R (2006) Combined passive and active immunoprophylaxis for preventing perinatal transmission of the hepatitis B virus in infants born to HBsAg positive mothers in comparison with vaccine alone. Hepatol Res 36:265–271
Kalantarov GF, Rudchenko SA, Lobel L, Trakht I (2002) Development of a fusion partner cell line for efficient production of human monoclonal antibodies from peripheral blood lymphocytes. Hum Antibodies 11:85–96
Kang AS, Jones TM, Burton DR (1991) Antibody redesign by chain shuffling from random combinatorial immunoglobulin libraries. Proc Natl Acad Sci U S A 88:11120–11123
Kanzaki Y, Onoue F, Sakurai H, Ide T (2003) Telomerase upregulates expression levels of interleukin (IL)-1alpha, IL-1beta, IL-6, IL-8, and granulocyte-macrophage colony-stimulating factor in normal human fibroblasts. Biochem Biophys Res Commun 305:150–154
Karpas A, Dremucheva A, Czepulkowski BH (2001) A human myeloma cell line suitable for the generation of human monoclonal antibodies. Proc Natl Acad Sci U S A 98:1799–1804
Keller MA, Stiehm ER (2000) Passive immunity in prevention and treatment of infectious diseases. Clin Microbiol Rev 13:602–614
Kirman I, Kalantarov GF, Lobel LI, Hibshoosh H, Estabrook A, Canfield R, Trakht I (2002) Isolation of native human monoclonal autoantibodies to breast cancer. Hybrid Hybridomics 21:405–414
Kitamura K, Yamada K, Kuzushima K, Morishima T, Morishima Y, Yamamoto N, Nishiyama Y, Ohya K, Yamaguchi H (1990) Human monoclonal antibodies to human cytomegalovirus derived from peripheral blood lymphocytes of healthy adults. J Med Virol 32:60–66
Kocher AA, Bonaros N, Dunkler D, Ehrlich M, Schlechta B, Zweytick B, Grimm M, Zuckermann A, Wolner E, Laufer G (2003) Long-term results of CMV hyperimmune globulin prophylaxis in 377 heart transplant recipients. J Heart Lung Transplant 22:250–257
Koropatnick J, Pearson J, Harris JF (1988) Extensive loss of human DNA accompanies loss of antibody production in heteromyeloma hybridoma cells. Mol Biol Med 5:69–83
Kozbor D, Roder JC, Chang TH, Steplewski Z, Koprowski H (1982) Human anti-tetanus toxoid monoclonal antibody secreted by EBV-transformed human B cells fused with murine myeloma. Hybridoma 1:323–328
Kozbor D, Roder JC, Sierzega ME, Cole SP, Croce CM (1986) Comparative phenotypic analysis of available human hybridoma fusion partners. Methods Enzymol 121:120–140
Krause I, Wu R, Sherer Y, Patanik M, Peter JB, Shoenfeld Y (2002) In vitro antiviral and antibacterial activity of commercial intravenous immunoglobulin preparations—a potential role for adjuvant intravenous immunoglobulin therapy in infectious diseases. Transfus Med 12:133–139
Krenn V, von Landenberg P, Wozniak E, Kissler C, Hermelink HK, Zimmermann U, Vollmers HP (1995) Efficient immortalization of rheumatoid synovial tissue B-lymphocytes. A comparison between the techniques of electric field-induced and PEG fusion. Hum Antibodies Hybridomas 6:47–51
Lafon M, Edelman L, Bouvet JP, Lafage M, Montchatre E (1990) Human monoclonal antibodies specific for the rabies virus glycoprotein and N protein. J Gen Virol 71:1689–1696
Lane JM, Ruben FL, Neff JM, Millar JD (1969) Complications of smallpox vaccination, 1968. N Engl J Med 281:1201–1208
Lanzavecchia A, Bernasconi N, Traggiai E, Ruprecht CR, Corti D, Sallusto F (2006) Understanding and making use of human memory B cells. Immunol Rev 211:303–309
Larrick JW, Truitt KE, Raubitschek AA, Senyk G, Wang JC (1983) Characterization of human hybridomas secreting antibody to tetanus toxoid. Proc Natl Acad Sci U S A 80:6376–6380
Law M, Smith GL (2001) Antibody neutralization of the extracellular enveloped form of vaccinia virus. Virology 280:132–142
Lewis AP, Lemon SM, Barber KA, Murphy P, Parry NR, Peakman TC, Sims MJ, Worden J, Crowe JS (1993) Rescue, expression, and analysis of a neutralizing human anti-hepatitis A virus monoclonal antibody. J Immunol 151:2829–2838
Lewis FM, Chernak E, Goldman E, Li Y, Karem K, Damon IK, Henkel R, Newbern EC, Ross P, Johnson CC (2006) Ocular vaccinia infection in laboratory worker, Philadelphia, 2004. Emerg Infect Dis 12:134–137
Lo KJ, Tsai YT, Lee SD, Wu TC, Wang JY, Chen GH, Yeh CL, Chiang BN, Yeh SH, Goudeau A, et al (1985) Immunoprophylaxis of infection with hepatitis B virus in infants born to hepatitis B surface antigen-positive carrier mothers. J Infect Dis 152:817–822
Love JC, Ronan JL, Grotenbreg GM, van der Veen AG, Ploegh HL (2006) A microengraving method for rapid selection of single cells producing antigen-specific antibodies. Nat Biotechnol 24:703–707
Meijer PJ, Andersen PS, Haahr Hansen M, Steinaa L, Jensen A, Lantto J, Oleksiewicz MB, Tengbjerg K, Poulsen TR, Coljee VW, Bregenholt S, Haurum JS, Nielsen LS (2006) Isolation of human antibody repertoires with preservation of the natural heavy and light chain pairing. J Mol Biol 358:764–772
Moudgil A, Shidban H, Nast CC, Bagga A, Aswad S, Graham SL, Mendez R, Jordan SC (1997) Parvovirus B19 infection-related complications in renal transplant recipients: treatment with intravenous immunoglobulin. Transplantation 64:1847–1850
Ohizumi Y, Suzuki H, Matsumoto Y, Masuho Y, Numazaki Y (1992) Neutralizing mechanisms of two human monoclonal antibodies against human cytomegalovirus glycoprotein 130/55. J Gen Virol 73:2705–2707
Ohlin M, Borrebaeck CA (1996) Characteristics of human antibody repertoires following active immune responses in vivo. Mol Immunol 33:583–592
Ohlin M, Sundqvist VA, Mach M, Wahren B, Borrebaeck CA (1993) Fine specificity of the human immune response to the major neutralization epitopes expressed on cytomegalovirus gp58/116 (gB), as determined with human monoclonal antibodies. J Virol 67:703–710
Olsson L, Kronstrom H, Cambon-De Mouzon A, Honsik C, Brodin T, Jakobsen B (1983) Antibody producing human-human hybridomas. I. Technical aspects. J Immunol Methods 61:17–32
Oral HB, Ozakin C, Akdis CA (2002) Back to the future: antibody-based strategies for the treatment of infectious diseases. Mol Biotechnol 21:225–239
Oshimura M, Barrett JC (1997) Multiple pathways to cellular senescence: role of telomerase repressors. Eur J Cancer 33:710–715
Panova I, Gustafsson B (1995) Increased human hybridoma formation by electrofusion of human B cells with heteromyeloma SPAM-8 cells. Hybridoma 14:265–269
Pavoni E, Monteriu G, Cianfriglia M, Minenkova O (2006) New display vector reduces biological bias for expression of antibodies in E. coli. Gene 391:120–129
Pereira-Smith OM, Robetorye S, Ning Y, Orson FM (1990) Hybrids from fusion of normal human T lymphocytes with immortal human cells exhibit limited life span. J Cell Physiol 144:546–549
Perkins S, Zimmermann U, Foung SK (1991) Parameters to enhance human hybridoma formation with hypoosmolar electrofusion. Hum Antibodies Hybridomas 2:155–159
Posner MR, Elboim H, Santos D (1987) The construction and use of a human-mouse myeloma analogue suitable for the routine production of hybridomas secreting human monoclonal antibodies. Hybridoma 6:611–625
Potera C (2005) Filling the niche for effective MAb screening. Genet Eng News 25
Pratt M, Mikhalev A, Glassy MC (1987) The generation of Ig-secreting UC 729–6 derived human hybridomas by electrofusion. Hybridoma 6:469–477
Ramirez JC, Tapia E, Esteban M (2002) Administration to mice of a monoclonal antibody that neutralizes the intracellular mature virus form of vaccinia virus limits virus replication efficiently under prophylactic and therapeutic conditions. J Gen Virol 83:1059–1067
Redfield RR, Wright DC, James WD, Jones TS, Brown C, Burke DS (1987) Disseminated vaccinia in a military recruit with human immunodeficiency virus (HIV) disease. N Engl J Med 316:673–676
Redmond MJ, Leyritz-Wills M, Winger L, Scraba DG (1986) The selection and characterization of human monoclonal antibodies to human cytomegalovirus. J Virol Methods 14:9–24
Rioux JD, Larose Y, Brodeur BR, Radzioch D, Newkirk MM (1994) Structural characteristics of four human hybridoma antibodies specific for the pp65 protein of the human cytomegalovirus and their relationship to human rheumatoid factors. Mol Immunol 31:585–597
Rodriguez WJ, Gruber WC, Welliver RC, Groothuis JR, Simoes EA, Meissner HC, Hemming VG, Hall CB, Lepow ML, Rosas AJ, Robertsen C, Kramer AA (1997) Respiratory syncytial virus (RSV) immune globulin intravenous therapy for RSV lower respiratory tract infection in infants and young children at high risk for severe RSV infections: Respiratory Syncytial Virus Immune Globulin Study Group. Pediatrics 99:454–461
Ruttmann E, Geltner C, Bucher B, Ulmer H, Hofer D, Hangler HB, Semsroth S, Margreiter R, Laufer G, Muller LC (2006) Combined CMV prophylaxis improves outcome and reduces the risk for bronchiolitis obliterans syndrome (BOS) after lung transplantation. Transplantation 81:1415–1420
Sa’adu A, Locniskar M, Bidwell D, Howard C, McAdam KP, Voller A (1992) Development and characterization of human anti-HBs antibodies. J Virol Methods 36:25–34
Saphire EO, Parren PW, Pantophlet R, Zwick MB, Morris GM, Rudd PM, Dwek RA, Stanfield RL, Burton DR, Wilson IA (2001) Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design. Science 293:1155–1159
Sawyer LA (2000) Antibodies for the prevention and treatment of viral diseases. Antiviral Res 47:57–77
Schlom J, Wunderlich D, Teramoto YA (1980) Generation of human monoclonal antibodies reactive with human mammary carcinoma cells. Proc Natl Acad Sci U S A 77: 6841–6845
Schmidt E, Leinfelder U, Gessner P, Zillikens D, Brocker EB, Zimmermann U (2001) CD19+ B lymphocytes are the major source of human antibody-secreting hybridomas generated by electrofusion. J Immunol Methods 255:93–102
Sechet A, Bridoux F, Bauwens M, Ayache RA, Belmouaz S, Touchard G (2002) Prevention of cytomegalovirus infection and disease in high-risk renal transplant recipients with polyvalent intravenous immunoglobulins. Transplant Proc 34:812–813
Shay DK, Holman RC, Roosevelt GE, Clarke MJ, Anderson LJ (2001) Bronchiolitis-associated mortality and estimates of respiratory syncytial virus-associated deaths among US children, 1979–1997. J Infect Dis 183:16–22
Shirahata S, Katakura Y, Teruya K (1998) Cell hybridization, hybridomas, and human hybridomas. Methods Cell Biol 57:111–145
Shulman M, Wilde CD, Kohler G (1978) A better cell line for making hybridomas secreting specific antibodies. Nature 276:269–270
Siemoneit K, da Silva Cardoso M, Wolpl A, Koerner K, Subanek B (1994) Isolation and epitope characterization of human monoclonal antibodies to hepatitis C virus core antigen. Hybridoma 13:9–13
Small TN, Casson A, Malak SF, Boulad F, Kiehn TE, Stiles J, Ushay HM, Sepkowitz KA (2002) Respiratory syncytial virus infection following hematopoietic stem cell transplantation. Bone Marrow Transplant 29:321–327
Smith GL, Vanderplasschen A, Law M (2002) The formation and function of extracellular enveloped vaccinia virus. J Gen Virol 83:2915–2931
Smith LL, Coller HA, Roberts JM (2003) Telomerase modulates expression of growth-controlling genes and enhances cell proliferation. Nat Cell Biol 5:474–479
Snydman DR, Werner BG, Heinze-Lacey B, Berardi VP, Tilney NL, Kirkman RL, Milford EL, Cho SI, Bush HL Jr, Levey AS, et al (1987) Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients. N Engl J Med 317:1049–1054
Sokos DR, Berger M, Lazarus HM (2002) Intravenous immunoglobulin: appropriate indications and uses in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 8:117–130
Stein LD, Sigal NH (1983) Limiting dilution analysis of Epstein-Barr virus-induced immunoglobulin production. Cell Immunol 79:309–319
Stewart SA, Hahn WC, O’Connor BF, Banner EN, Lundberg AS, Modha P, Mizuno H, Brooks MW, Fleming M, Zimonjic DB, Popescu NC, Weinberg RA (2002) Telomerase contributes to tumorigenesis by a telomere length-independent mechanism. Proc Natl Acad Sci USA 99:12606–12611
Stricker EA, Tiebout RF, Lelie PN, Zeijlemaker WP (1985) A human monoclonal IgG1 lambda anti-hepatitis B surface antibody. Production, properties, and applications. Scand J Immunol 22:337–343
Sugano T, Matsumoto Y, Miyamoto C, Masuho Y (1987) Hybridomas producing human monoclonal antibodies against varicella-zoster virus. Eur J Immunol 17:359–364
Sugano T, Tomiyama T, Matsumoto Y, Sasaki S, Kimura T, Forghani B, Masuho Y (1991) A human monoclonal antibody against varicella-zoster virus glycoprotein III. J Gen Virol 72:2065–2073
Tan MP, Koren G (2006) Chickenpox in pregnancy: revisited. Reprod Toxicol 21:410–420
Terrault NA, Vyas G (2003) Hepatitis B immune globulin preparations and use in liver transplantation. Clin Liver Dis 7:537–550
Terrault NA, Zhou S, McCory RW, Pruett TL, Lake JR, Roberts JP, Ascher NL, Wright TL (1998) Incidence and clinical consequences of surface and polymerase gene mutations in liver transplant recipients on hepatitis B immunoglobulin. Hepatology 28:555–561
Thompson JM, Lowe J, McDonald DF (1994) Human monoclonal anti-D secreting heterohybridomas from peripheral B lymphocytes expanded in the CD40 system. J Immunol Methods 175:137–140
Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, Anderson LJ, Fukuda K (2003) Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 289:179–186
Tian C, Luskin GK, Dischert KM, Higginbotham JN, Shepherd BE, Crowe JE Jr (2007) Evidence for preferential Ig gene usage and differential TdT and exonuclease activities in human naive and memory B cells. Mol Immunol 44:2173–2183
Tiebout RF, van Boxtel-Oosterhof F, Stricker EA, Zeijlemaker WP (1987) A human hybrid hybridoma. J Immunol 139:3402–3405
Traggiai E, Becker S, Subbarao K, Kolesnikova L, Uematsu Y, Gismondo MR, Murphy BR, Rappuoli R, Lanzavecchia A (2004) An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. Nat Med 10:871–875
Ueki Y, Goldfarb IS, Harindranath N, Gore M, Koprowski H, Notkins AL, Casali P (1990) Clonal analysis of a human antibody response. Quantitation of precursors of antibody-producing cells and generation and characterization of monoclonal IgM, IgG, and IgA to rabies virus. J Exp Med 171:19–34
Vaisbourd M, Ignatovich O, Dremucheva A, Karpas A, Winter G (2001) Molecular characterization of human monoclonal antibodies derived from fusions of tonsil lymphocytes with a human myeloma cell line. Hybrid Hybridomics 20:287–292
Varga M, Remport A, Hidvegi M, Peter A, Kobori L, Telkes G, Fazakas J, Gerlei Z, Sarvary E, Sulyok B, Jaray J (2005) Comparing cytomegalovirus prophylaxis in renal transplantation: single center experience. Transpl Infect Dis 7:63–67
Welliver RC (2003) Respiratory syncytial virus and other respiratory viruses. Pediatr Infect Dis J 22: S6–S10; discussion S10–S12
Winter G, Griffiths AD, Hawkins RE, Hoogenboom HR (1994) Making antibodies by phage display technology. Annu Rev Immunol 12:433–455
Xiao XM, Li AZ, Chen X, Zhu YK, Miao J (2007) Prevention of vertical hepatitis B transmission by hepatitis B immunoglobulin in the third trimester of pregnancy. Int J Gynaecol Obstet 96:167–170
Xu JL, Davis MM (2000) Diversity in the CDR3 region of V(H) is sufficient for most antibody specificities. Immunity 13:37–45
Xu Q, Xiao L, Lu XB, Zhang YX, Cai X (2006) A randomized controlled clinical trial: interruption of intrauterine transmission of hepatitis B virus infection with HBIG. World J Gastroenterol 12:3434–3437
Yoshinari K, Arai K, Kimura H, Matsumoto K, Yamaguchi Y (1996) Efficient production of IgG human monoclonal antibodies by lymphocytes stimulated by lipopolysaccharide, pokeweed mitogen, and interleukin 4. In Vitro Cell Dev Biol Anim 32:372–377
Young J (2002) Development of a potent respiratory syncytial virus-specific monoclonal antibody for the prevention of serious lower respiratory tract disease in infants. Respir Med 96 [Suppl B]:S31–35
Zhu Y, Jin B, Sun C, Huang C, Liu X (1993) The effects of hybridoma growth factor in conditioned media upon the growth, cloning, and antibody production of heterohybridoma cell lines. Hum Antibodies Hybridomas 4:31–35
Zhu Y, Jin B, Jiang S, Sun K, Sun C, Liu X (1999) Improved fusion partners transfected with DNA fragment encoding IL-11 on generation of human B lymphocyte hybridomas. Hum Antibodies 9:1–7
Zikos P, Van Lint MT, Lamparelli T, Gualandi F, Occhini D, Mordini N, Berisso G, Bregante S, Bacigalupo A (1998) A randomized trial of high dose polyvalent intravenous immunoglobulin (HDIgG) vs. Cytomegalovirus (CMV) hyperimmune IgG in allogeneic hemopoietic stem cell transplants (HSCT). Haematologica 83:132–137
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Dessain, S.K., Adekar, S.P., Berry, J.D. (2008). Exploring the Native Human Antibody Repertoire to Create Antiviral Therapeutics. In: Dessain, S.K. (eds) Human Antibody Therapeutics for Viral Disease. Current Topics in Microbiology and Immunology, vol 317. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-72146-8_6
Download citation
DOI: https://doi.org/10.1007/978-3-540-72146-8_6
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-72144-4
Online ISBN: 978-3-540-72146-8
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)